Pacira BioSciences (FRA:82P) Cyclically Adjusted Book per Share: €12.91 (As of Mar. 2026)


FRA:82P Pacira BioSciences Inc FRA:82P
75 GF Score
Price €22.00
GF Value €25.55
! 8 Warning Signs
View Full Analysis

What is Pacira BioSciences Cyclically Adjusted Book per Share?

Pacira BioSciences FRA:82P -1.79% 75 Cyclically Adjusted Book per Share is €12.91 as of Mar. 2026. GuruFocus rates FRA:82P with a GF Score™ of 75/100 and a GF Value™ of €25.55. The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Pacira BioSciences's adjusted book value per share for the three months ended in Mar. 2026 was €14.389. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €12.91 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Pacira BioSciences's average Cyclically Adjusted Book Growth Rate was 10.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 14.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 20.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Pacira BioSciences was 28.90% per year. The lowest was 14.80% per year. And the median was 22.60% per year.

As of today (2026-07-09), Pacira BioSciences's current stock price is €22.00. Pacira BioSciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €12.91. Pacira BioSciences's Cyclically Adjusted PB Ratio of today is 1.70.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Pacira BioSciences was 13.51. The lowest was 0.95. And the median was 5.48.


Pacira BioSciences  (FRA:82P) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Pacira BioSciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=22.00/12.91
=1.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Pacira BioSciences was 13.51. The lowest was 0.95. And the median was 5.48.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Pacira BioSciences Cyclically Adjusted Book per Share Related Terms


Pacira BioSciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences Cyclically Adjusted Book per Share Chart

Pacira BioSciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.80 8.79 10.07 12.86 11.83

Pacira BioSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.11 11.44 11.73 11.83 12.91

FRA:82P vs ETON, AMPH, BIOA: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Cyclically Adjusted PB Ratio falls into.


FRA:82P
75GF Score
Pacira BioSciences Inc FRA:82P
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacira BioSciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pacira BioSciences's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=14.389/330.2130*330.2130
=14.389

Current CPI (Mar. 2026) = 330.2130.

Pacira BioSciences Quarterly Data

Book Value per Share CPI Adj_Book
201606 5.453 241.018 7.471
201609 5.106 241.428 6.984
201612 5.539 241.432 7.576
201703 6.322 243.801 8.563
201706 5.763 244.955 7.769
201709 5.477 246.819 7.328
201712 5.807 246.524 7.778
201803 5.547 249.554 7.340
201806 6.072 251.989 7.957
201809 6.288 252.439 8.225
201812 6.850 251.233 9.003
201903 7.020 254.202 9.119
201906 7.267 256.143 9.368
201909 7.538 256.759 9.694
201912 7.623 256.974 9.796
202003 8.037 258.115 10.282
202006 8.089 257.797 10.361
202009 11.461 260.280 14.540
202012 11.673 260.474 14.798
202103 12.437 264.877 15.505
202106 12.835 271.696 15.599
202109 13.719 274.310 16.515
202112 14.450 278.802 17.115
202203 14.297 287.504 16.421
202206 15.628 296.311 17.416
202209 16.959 296.808 18.868
202212 15.929 296.797 17.722
202303 15.605 301.836 17.072
202306 16.069 305.109 17.391
202309 16.783 307.789 18.006
202312 17.166 306.746 18.479
202403 17.645 312.332 18.655
202406 17.713 314.175 18.617
202409 14.635 315.301 15.327
202412 16.075 315.605 16.819
202503 15.959 319.799 16.479
202506 14.633 322.561 14.980
202509 14.420 324.800 14.660
202512 14.396 324.054 14.670
202603 14.389 330.213 14.389

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €12.91 mean?
Pacira BioSciences (FRA:82P) has a Cyclically Adjusted Book per Share of €12.91 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Pacira BioSciences and its competitors.
Is Pacira BioSciences' Cyclically Adjusted Book per Share too high?
Pacira BioSciences' current Cyclically Adjusted Book per Share is €12.91. Overall, Pacira BioSciences has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Cyclically Adjusted Book per Share compare to ETON and AMPH?
Pacira BioSciences' Cyclically Adjusted Book per Share of €12.91 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current Cyclically Adjusted Book per Share is €12.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Cyclically Adjusted Book per Share of €12.91. The stock's GF Value™ is €25.55, compared to a current price of €22.00 — trading 13.9% below its estimated fair value. The current Cyclically Adjusted Book per Share is €12.91. Pacira BioSciences' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Cyclically Adjusted Book per Share is €12.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (FRA:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €22.00 is trading 13.9% below its estimated GF Value™ of €25.55.

Key valuation signals for FRA:82P:

  • Cyclically Adjusted Book per Share: €12.91
  • GF Value™: €25.55 vs. price of €22.00 (13.9% below fair value)
  • GF Score™: 75/100 with 8 warning signs

No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacira BioSciences Business Description

Other Exchanges PCRX:USA82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
75GF Score

Get the complete analysis for FRA:82P

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.00
Price
€25.55
GF Value